Oak Grove Capital LLC Has $1.35 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Oak Grove Capital LLC cut its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.9% during the second quarter, Holdings Channel.com reports. The institutional investor owned 2,580 shares of the biopharmaceutical company’s stock after selling 450 shares during the quarter. Oak Grove Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $1,354,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Founders Capital Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 7.0% in the second quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock worth $4,344,000 after acquiring an additional 538 shares during the last quarter. PGGM Investments raised its stake in shares of Regeneron Pharmaceuticals by 159.7% in the second quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock worth $44,308,000 after acquiring an additional 51,900 shares during the last quarter. Sepio Capital LP raised its stake in shares of Regeneron Pharmaceuticals by 33.1% in the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock worth $2,150,000 after acquiring an additional 842 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Regeneron Pharmaceuticals by 3.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company’s stock worth $16,255,000 after acquiring an additional 955 shares during the last quarter. Finally, Generate Investment Management Ltd bought a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $6,300,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on REGN shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a research note on Saturday. Rothschild & Co Redburn assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday, August 14th. They issued a “buy” rating and a $890.00 target price for the company. Canaccord Genuity Group reissued a “buy” rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday. Jefferies Financial Group boosted their price target on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a research note on Wednesday, August 27th. Finally, Citigroup boosted their price target on shares of Regeneron Pharmaceuticals from $650.00 to $660.00 and gave the stock a “buy” rating in a research note on Monday, October 13th. Three analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $802.35.

Regeneron Pharmaceuticals Trading Up 0.4%

REGN opened at $577.95 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The company has a market cap of $61.26 billion, a price-to-earnings ratio of 14.57, a price-to-earnings-growth ratio of 1.80 and a beta of 0.31. The firm has a 50 day simple moving average of $576.32 and a 200 day simple moving average of $562.53. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $943.83.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. The firm had revenue of $3.68 billion during the quarter, compared to analysts’ expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $11.56 earnings per share. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were issued a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is currently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.